VCU Health’s Post

Tonight, CURE® and Voices of MPN came together to recognize the heroes who have made a difference in the lives of patients with myeloproliferative neoplasms (MPNs). Learn more about the program and the 2023 class of MPN Heroes®. https://bit.ly/48bghc6

In this edition of In The Network, we share three patient stories that showcase triumphs during cancer challenges and how AON practices have impacted the patients’ lives. Read the article > https://hubs.li/Q02mM0Tw0 #InTheNetwork #CancerCare #WeAreAON

Today’s figures show we are making headway towards our goal to cut waiting lists.       ❤️🩹 The overall waiting list has dropped by almost 200,000 in the last 5 months    🧑⚕️ One and a half year waits for treatment are now the lowest since the pandemic    🚑 Ambulance and 4-hour A&E waits have improved significantly over the last year       I know there is still work to do but this shows what the NHS can do for patients.     With the hard work of our brilliant NHS staff and our investment into innovations like Community Diagnostic Centres, which help get patients the care they need quicker, we can cut waiting lists.         We promised to have CDCs rolled out in 160 sites by March 2025 to diagnose illnesses like cancer and heart disease quicker, and we’ve already hit that milestone – nearly a whole year ahead of schedule.          With innovations like this and record staff in the NHS we’ll continue to make positive progress on cutting waiting lists. Find out more: https://lnkd.in/eTATeEwz

Today is about showing others that you care for them, whether in small ways or grand gestures. At Onco360, our patients are at the heart of everything we do. Every interaction is filled with a dose of care, kindness, and most of all – compassion. Learn more at https://lnkd.in/eECvStpW. #OncologyPharmacy #ValentinesDay

Modern Healthcare is truly remarkable

National Minority Donor Awareness Day (The first day of National Minority Donor Awareness Week) is observed at the beginning of August each year. This event is meant to honor the contribution of donors and donor families from a wide array of cultural and ethnic backgrounds, while also highlighting the urgent need from members of minority communities to register themselves as organ, eye, and tissue donors. Although it is not necessary to the success of a transplant for a donor and recipient to be from the same racial or ethnic group, transplant success rates increase when such a match can be made! Blood type is one of the most significant considerations made by healthcare providers when matching donors to recipients, and because certain blood types tend to be more prevalent among any given racial or ethnic group, there is a higher likelihood of a recipient and donor matching if they are both members of said group. Again, this is not absolutely necessary, but any opportunity to increase the number of successful transplants should be taken. We encourage you to raise awareness on this important issue in observance of this annual event!

Dear Friends, Families, and Supporters, We are beyond excited to share monumental news for the Niemann-Pick Type C (NPC) community! Just days after celebrating the FDA approval of the first-ever combination therapy for NPC, we have yet another reason to celebrate: the FDA has approved Aqneursa (Levacetylleucine) for the treatment of neurological manifestations of NPC, developed by IntraBio. This is the second FDA-approved treatment to combat this devastating disease—an achievement that fills us with renewed hope. This remarkable progress brings us closer to changing the landscape of NPC care. The introduction of multiple therapies in such a short time reflects the tireless dedication of NPC families, researchers, clinicians, and all of you—our incredible community of supporters. These back-to-back approvals underscore the urgency of finding viable treatments and demonstrate what is possible when we come together. The path toward these breakthroughs hasn't been easy, but it's been driven by unwavering belief that every NPC family deserves hope. These therapies offer more than just relief—they represent life-changing possibilities for our children and loved ones battling this cruel disease. At AbbyStrong Fights NPC, we remain committed to advocating, supporting research, and pushing forward, with the ultimate goal of finding a cure. Today's news is a pivotal step, but we still have more work to do. Your continued support means everything as we move towards a future where no family will have to face NPC without hope. Please join us in celebrating this incredible milestone. Together, we will continue to push boundaries, uplift families, and strive for a cure. Together, we will beat NPC. With deep gratitude, Garland Alvey Co-Founder and Executive Director AbbyStrong Fights NPC https://lnkd.in/eDGkZKpw

Today, LaVarne A. Burton, President and CEO of the American Kidney Fund was on Capitol Hill with other leaders in the kidney community to discuss equitable kidney care and breaking down barriers in screening, diagnosis and treatment. AKF urges the United States Preventive Services Task Force (USPSTF) to recommend kidney disease screenings for people at high risk for kidney disease. We believe that making meaningful changes to preventative care recommendations will make a significant impact in addressing the health disparities seen in kidney disease. We are proud to be leading efforts on this front through our Kidney Health for All™ initiative, which focuses on actionable solutions so that race and ethnicity will no longer play a significant role in kidney health outcomes. While there is still more work to be done, we urge Congress to support a federal screening recommendation. We thank Larry Bucshon and Suzan DelBene for their support. #KidneyHealthforAll Read more - https://lnkd.in/guGCM97m Pictured left to right: Edward V. Hickey, III, President, American Association of Kidney Patients, Dr. Susan Quaggin, Immediate Past President, American Society of Nephrology, Dr. Sylvia Rosas, Associate Professor of Medicine at Harvard Medical School and President, National Kidney Foundation, LaVarne A. Burton, President and Chief Executive Officer, American Kidney Fund, Freeway – Platinum Recording Artist & Advocate, Kevin Bernier, Head of Patient Advocacy, Bayer

Unused Donor Kidneys Increased Again in 2023 The most recent UNOS/OPTN data clearly emphasizes the critical role 34 Lives will play in rescuing donor kidneys. In 2023, there were 8,574 kidneys recovered with the intent to transplant, but later discarded. This represents 28% of the total (one percent higher, or 1,000 more, than in 2022!). Using OPTN National Data, I created this graph to illustrate the growing scope of the problem with Hard-to-Place kidneys, the focus of our upcoming clinical study. Data such as these motivate us even more to move forward with urgency and commitment. Thanks for your support and commitment, Chris Jaynes, CEO [Reference: transplant.hrsa.gov]

It is important for everyone to know that they have a seat at the table when changes to the national donation and transplant system are being considered. This is especially true of transplant candidates, recipients, care partners, living donors, donor families and everyone else invested in their well being. You do not need to be an expert on policy or the clinical details to share what is important to you, and how changes may impact you on a personal level. Please join us to learn more about how YOUR VOICE MATTERS! There is no wrong way to participate!